Literature DB >> 17170334

Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.

N F Kelland, D J Webb.   

Abstract

The failure of endothelin antagonists to show benefit in heart failure cannot be understood until all the clinical trials are fully published.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17170334      PMCID： PMC1861328          DOI： 10.1136/hrt.2006.089250

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  41 in total

1.  Endothelin antagonists and hypertension: a question of dose?

Authors:  Jane Goddard; David J Webb
Journal:  Hypertension       Date:  2002-09       Impact factor: 10.190

2.  Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?

Authors:  John R Teerlink
Journal:  J Card Fail       Date:  2002-06       Impact factor: 5.712

3.  Nonselective endothelin receptor antagonist initiated soon after the onset of myocardial infarction may deteriorate 24-hour survival.

Authors:  C Takahashi; Y Kagaya; S Namiuchi; M Takeda; M Fukuchi; H Otani; M Ninomiya; Y Yamane; M Kohzuki; J Watanabe; K Shirato
Journal:  J Cardiovasc Pharmacol       Date:  2001-07       Impact factor: 3.105

4.  Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade.

Authors:  J P Halcox; K R Nour; G Zalos; A A Quyyumi
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

Review 5.  International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature.

Authors:  Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

6.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

7.  ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

Authors:  Neil Davie; Stephen J Haleen; Paul D Upton; Julia M Polak; Magdi H Yacoub; Nicholas W Morrell; John Wharton
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

8.  Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing.

Authors:  Q T Nguyen; P Cernacek; M G Sirois; A Calderone; N Lapointe; D J Stewart; J L Rouleau
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

9.  Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.

Authors:  J C Spratt; J Goddard; N Patel; F E Strachan; A J Rankin; D J Webb
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

10.  Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

Authors:  G Sütsch; W Kiowski; X W Yan; P Hunziker; S Christen; W Strobel; J H Kim; P Rickenbacher; O Bertel
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690
View more
  10 in total

1.  Right-sided heart failure: diagnosis and treatment strategies.

Authors:  Jennifer Cowger Matthews; Todd F Dardas; Michael P Dorsch; Keith D Aaronson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

2.  Neurohormonal Blockade in Heart Failure.

Authors:  Thomas G von Lueder; Dipak Kotecha; Dan Atar; Ingrid Hopper
Journal:  Card Fail Rev       Date:  2017-04

Review 3.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.

Authors:  Marc Q Mazzuca; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

Review 4.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

Review 5.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

6.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 7.  Endothelins in cardiovascular biology and therapeutics.

Authors:  Neeraj Dhaun; David J Webb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

Review 8.  The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth.

Authors:  Faye M Drawnel; Caroline R Archer; H Llewelyn Roderick
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

9.  Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.

Authors:  Rhoda E Kuc; Myrna Carlebur; Janet J Maguire; Peiran Yang; Lu Long; Mark Toshner; Nicholas W Morrell; Anthony P Davenport
Journal:  Life Sci       Date:  2014-02-26       Impact factor: 5.037

10.  Structural heart defects associated with ETB mutation, a cause of Hirschsprung disease.

Authors:  Ko-Chin Chen; Ko-Chien Chen; Zan-Min Song; Geoffrey D Croaker
Journal:  BMC Cardiovasc Disord       Date:  2021-10-02       Impact factor: 2.298
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.